

## [N-Oxide analogs of WAY-100635: new high affinity 5-HT<sub>1A</sub> receptor antagonists](#)

Marchais-Oberwinkler, S. / Nowicki, B. / Pike, V.W. / Halldin, C. / Sandell, J. / Chou, Y.-H. / Gulyas, B. / Brennum, L.T. / Farde, L. / Wikstrom, H.V., *Bioorganic and Medicinal Chemistry*, Feb 2005

WAY-100635 [N-(2-(1-(4-(2-methoxyphenyl)piperazinyl)ethyl))-N-(2-pyridinyl)cyclohexanecarboxamide] **1** and its O-desmethyl derivative DWAY **2** are well-known high affinity 5-HT<sub>1A</sub> receptor antagonists, which when labeled with carbon-11...

## N-Oxide analogs of WAY-100635: new high affinity 5-HT<sub>1A</sub> receptor antagonists

Sandrine Marchais-Oberwinkler<sup>a</sup>, Bartek Nowicki<sup>a</sup>, Victor W. Pike<sup>b</sup>, Christer Halldin<sup>c</sup>, Johan Sandell<sup>c</sup>, Yuan-Hwa Chou<sup>c</sup>, Balazs Gulyas<sup>c</sup>, Lise T. Brennum<sup>d</sup>, Lars Farde<sup>c</sup> and Håkan V. Wikström<sup>a</sup>

<sup>a</sup>Department of Medicinal Chemistry, University Center for Pharmacy, University of Groningen, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands

<sup>b</sup>PET Radiopharmaceutical Sciences, Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Room B3 C346A, 10 Center Drive, Bethesda, MD 20892-1003, USA

<sup>c</sup>Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital, S-17176 Stockholm, Sweden

<sup>d</sup>Department of Molecular Pharmacology, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby, Denmark


Received 18 November 2003; accepted 13 October 2004. Available online 17 November 2004.

### Abstract


WAY-100635 [N-(2-(1-(4-(2-methoxyphenyl)piperazinyl)ethyl))-N-(2-pyridinyl)cyclohexanecarboxamide] **1** and its *O*-desmethyl derivative DWAY **2** are well-known high affinity 5-HT<sub>1A</sub> receptor antagonists, which when labeled with carbon-11 ( $\beta^+$ ;  $t_{1/2} = 20.4$  min) in the carbonyl group are effective radioligands for imaging brain 5-HT<sub>1A</sub> receptors with positron emission tomography (PET). In a search for new 5-HT<sub>1A</sub> antagonists with different pharmacokinetic and metabolic properties, the pyridinyl *N*-oxide moiety was incorporated into analogs of **1** and **2**. NOWAY **3**, in which the pyridinyl ring of **1** was oxidized to the pyridinyl *N*-oxide, was prepared via nucleophilic substitution of 2-[4-(2-methoxyphenyl)piperazin-1-yl]ethylamine on 2-chloropyridine-*N*-oxide followed by acylation with cyclohexanecarbonyl chloride. 6Cl-NOWAY **4**, a more lipophilic (*pyridinyl*-6)-chloro derivative of **3**, was prepared by treating 1-(2-methoxyphenyl)-4-(2-(6-bromo)aminopyridinyl-*N*-oxide)ethylpiperazine with cyclohexanecarbonyl chloride for acylation and concomitant chloro for bromo substitution. NEWWAY **5**, in which the 2-hydroxy-phenyl group of **2** is replaced with a 2-pyridinyl *N*-oxide group with the intention of mimicking the topology of **2**, was prepared in five steps from 2-(chloroacetyl-amino)pyridine. *N*-Oxides **3**–**5** were found to be high affinity antagonists at 5-HT<sub>1A</sub> receptors, with **3** having the highest affinity and a  $K_i$  value (0.22 nM) comparable to that of **1** (0.17 nM). By

calculation the lipophilicity of **3** ( $\text{Log } P = 1.87$ ) is lower than that of **1** by 1.25  $\text{Log } P$  units while TLC and reverse phase HPLC indicate that **3** has slightly lower lipophilicity than **1**. On the basis of these encouraging findings, the *N*-oxide **3** was selected for labeling with carbon-11 in its carbonyl group and for evaluation as a radioligand with PET. After intravenous injection of [*carbonyl*- $^{11}\text{C}$ ]**3** into cynomolgus monkey there was very low uptake of radioactivity into brain and no PET image of brain 5-HT<sub>1A</sub> receptors was obtained. Either **3** inadequately penetrates the blood–brain barrier or it is excluded from brain by an active efflux mechanism. Rapid deacylation of **3** was not apparent *in vivo*; in cynomolgus monkey plasma radioactive metabolites of [*carbonyl*- $^{11}\text{C}$ ]**3** appeared less rapidly than from the radioligands [*carbonyl*- $^{11}\text{C}$ ]**1** and [*carbonyl*- $^{11}\text{C}$ ]**2**, which are known to be primarily metabolized by deacylation. Ligand **3** may have value as a new pharmacological tool, but not as a radioligand for brain imaging.

## Graphical abstract



**Keywords:** WAY-100635; 5-HT<sub>1A</sub> Receptor antagonist; High affinity; Pyridinyl *N*-oxide; PET; Aromatic nucleophilic substitution

 Corresponding author at present address: Pharmazeutische und Medizinische Chemie, Universität des Saarlandes, Postfach 151150, D-66041 Saarbrücken, Germany. Tel.: +49 681 3022484; fax: +49 681 3024386

[Bioorganic & Medicinal Chemistry](#)

[Volume 13, Issue 3](#), 1 February 2005, Pages 883-893

[Full article available from Science Direct](#)